SEATTLE--NeoRx Corporation reports that in phase I/II dose escalation
studies, Avicidin produced a 10-fold improvement in tumor-to-blood
ratios over conventional radioimmunotherapy, approaching the ratios
achieved in animal studies.
Avicidin, a monoclonal antibody/yttrium-90 product, employs NeoRx's
proprietary pretargeting technology in which the radionuclide
and antibody are injected separately rather than linked together.
The radionuclide either attaches to the antibody that is pretargeted
to the tumor or quickly exits the body, reducing radiation exposure
to normal tissues, NeoRx said.